BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 23388003)

  • 1. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
    N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
    Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin and mortality in acutely ill medical patients.
    Kakkar AK; Cimminiello C; Goldhaber SZ; Parakh R; Wang C; Bergmann JF;
    N Engl J Med; 2011 Dec; 365(26):2463-72. PubMed ID: 22204723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
    Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
    N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
    Mebazaa A; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Merli G; Schellong SW; Spyropoulos AC; Tapson VF; De Sanctis Y; Cohen AT
    Circulation; 2014 Jul; 130(5):410-8. PubMed ID: 24970782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for thromboprophylaxis.
    Lotke PA
    N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
    Samama MM; Cohen AT; Darmon JY; Desjardins L; Eldor A; Janbon C; Leizorovicz A; Nguyen H; Olsson CG; Turpie AG; Weisslinger N
    N Engl J Med; 1999 Sep; 341(11):793-800. PubMed ID: 10477777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
    ; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
    N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for thromboprophylaxis.
    ten Cate H; Hamulyak K
    N Engl J Med; 2008 Nov; 359(20):2174-5; author reply 2176. PubMed ID: 19009676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 46.